Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.
Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA. Fritzler MJ, et al. Among authors: kalden jr. J Rheumatol. 2003 Nov;30(11):2374-81. J Rheumatol. 2003. PMID: 14677180
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity.
Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA. Tan EM, et al. Among authors: kalden jr. Arthritis Rheum. 1999 Mar;42(3):455-64. doi: 10.1002/1529-0131(199904)42:3<455::AID-ANR10>3.0.CO;2-3. Arthritis Rheum. 1999. PMID: 10088768 Free article.
Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting.
Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Rothfield N, Takasaki Y, van Venrooij WJ, Tan EM. Smolen JS, et al. Among authors: kalden jr. Arthritis Rheum. 1997 Mar;40(3):413-8. doi: 10.1002/art.1780400304. Arthritis Rheum. 1997. PMID: 9082926
Range of antinuclear antibodies in "healthy" individuals.
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Tan EM, et al. Among authors: kalden jr. Arthritis Rheum. 1997 Sep;40(9):1601-11. doi: 10.1002/art.1780400909. Arthritis Rheum. 1997. PMID: 9324014
Advances in targeted therapy.
Breedveld FC, Kalden JR, Smolen JS. Breedveld FC, et al. Among authors: kalden jr. Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii1-ii2. doi: 10.1093/rheumatology/kew354. Rheumatology (Oxford). 2016. PMID: 27856653 No abstract available.
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B; Leflunomide Rheumatoid Arthritis Investigators Groups. Strand V, et al. Among authors: kalden jr. J Rheumatol. 2005 Apr;32(4):590-601. J Rheumatol. 2005. PMID: 15801012
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Antoni CE, et al. Among authors: kalden jr. J Rheumatol. 2008 May;35(5):869-76. Epub 2008 Mar 15. J Rheumatol. 2008. PMID: 18381786 Clinical Trial.
604 results